for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Beigene initiates pivotal trial of PD-1 antibody BGB-a317 in China

July 5 (Reuters) - Beigene Ltd

* Beigene initiates pivotal trial of PD-1 antibody BGB-a317 in China in patients with urothelial cancer

* Beigene Ltd - plan to expand development program for BGB-A317 in China and other geographies, both as monotherapy and in combination

* Beigene - trial’s primary endpoint is ORR according to response evaluation criteria in solid tumors version 1.1 as assessed by independent review Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up